ArticleRSC advances2025
Synthesis of SGLT2 inhibitor
Yu Liu, Xiaodong Fang, Meng Sun, Xutong Wang, Kejing Ma, Bing Wang, Qiming Li, Jan Mohammad Omar, Yihui Liu, Heng Liu and 1 more
Abstract read
In one paragraphArticle in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Yu LiuDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Xiaodong FangDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Meng SunDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Xutong WangDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Kejing MaDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Bing WangDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Qiming LiDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.
Jan Mohammad OmarSecond Affiliated Hospital of Harbin Medical University Harbin 150081 China 502986473@qq.com.
Yihui LiuSecond Affiliated Hospital of Harbin Medical University Harbin 150081 China 502986473@qq.com.
Heng LiuPharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University Harbin China 2454802160@qq.com.
Weina HanDepartment of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University Harbin People's Republic of China hanweina@hrbmu.edu.cn.ORCID https://orcid.org/0000-0001-7241-1608 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
SGLT2 inhibitors were derived from the natural product phlorizin and were used clinically to treat heart failure with preserved ejection fraction (HFpEF). In this study, based on phlorizin as the lead compound, tyramine moiety was introduced while retaining the pharmacophoric glucoside, thereby enhancing SGLT2 protein inhibitory activity and improving gastrointestinal absorption properties. We synthesized 11 new
Identifiers
PMID40584758
PMCPMC12203148
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390